JP2015518474A - 血液、血液生産物及び器官を処置する方法 - Google Patents

血液、血液生産物及び器官を処置する方法 Download PDF

Info

Publication number
JP2015518474A
JP2015518474A JP2015503890A JP2015503890A JP2015518474A JP 2015518474 A JP2015518474 A JP 2015518474A JP 2015503890 A JP2015503890 A JP 2015503890A JP 2015503890 A JP2015503890 A JP 2015503890A JP 2015518474 A JP2015518474 A JP 2015518474A
Authority
JP
Japan
Prior art keywords
seq
sequence number
peptide
sequence
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518474A5 (enExample
Inventor
ヴィルボルト ディーター
ヴィルボルト ディーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Jülich
Original Assignee
Forschungszentrum Jülich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE201210102999 external-priority patent/DE102012102999A1/de
Priority claimed from DE102012108599.4A external-priority patent/DE102012108599B4/de
Priority claimed from DE102012108598.6A external-priority patent/DE102012108598A1/de
Application filed by Forschungszentrum Jülich filed Critical Forschungszentrum Jülich
Publication of JP2015518474A publication Critical patent/JP2015518474A/ja
Publication of JP2015518474A5 publication Critical patent/JP2015518474A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • General Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
JP2015503890A 2012-04-05 2013-04-05 血液、血液生産物及び器官を処置する方法 Pending JP2015518474A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE102012102999.7 2012-04-05
DE201210102999 DE102012102999A1 (de) 2012-04-05 2012-04-05 Verfahren zur Behandlung von Blut, Blutprodukten und Organen
DE102012108599.4A DE102012108599B4 (de) 2012-09-14 2012-09-14 A-Beta-Oligomer-bindende Peptide und deren Verwendung
DE102012108598.6A DE102012108598A1 (de) 2012-09-14 2012-09-14 Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
DE102012108599.4 2012-09-14
DE102012108598.6 2012-09-14
PCT/EP2013/057160 WO2013150126A2 (de) 2012-04-05 2013-04-05 Verfahren zur behandlung von blut, blutprodukten und organen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017134929A Division JP6619394B2 (ja) 2012-04-05 2017-07-10 血液、血液生産物及び器官を処置する方法

Publications (2)

Publication Number Publication Date
JP2015518474A true JP2015518474A (ja) 2015-07-02
JP2015518474A5 JP2015518474A5 (enExample) 2016-09-15

Family

ID=48184148

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015503890A Pending JP2015518474A (ja) 2012-04-05 2013-04-05 血液、血液生産物及び器官を処置する方法
JP2017134929A Active JP6619394B2 (ja) 2012-04-05 2017-07-10 血液、血液生産物及び器官を処置する方法
JP2019206147A Active JP6997160B2 (ja) 2012-04-05 2019-11-14 血液、血液生産物及び器官を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017134929A Active JP6619394B2 (ja) 2012-04-05 2017-07-10 血液、血液生産物及び器官を処置する方法
JP2019206147A Active JP6997160B2 (ja) 2012-04-05 2019-11-14 血液、血液生産物及び器官を処置する方法

Country Status (8)

Country Link
US (3) US9591845B2 (enExample)
EP (2) EP2834643B1 (enExample)
JP (3) JP2015518474A (enExample)
CN (2) CN108926749A (enExample)
DK (2) DK2834643T3 (enExample)
ES (2) ES2938886T3 (enExample)
PL (1) PL3260865T3 (enExample)
WO (1) WO2013150126A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022529224A (ja) * 2019-04-05 2022-06-20 ファーマキュア リミテッド タンパク質凝集疾患の治療
JP2022158028A (ja) * 2021-04-01 2022-10-14 国立大学法人神戸大学 ペプチド結合切断活性を有する人工ペプチドおよびその利用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
JP2015518474A (ja) * 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 血液、血液生産物及び器官を処置する方法
DE102013016002A1 (de) 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung
US10995118B2 (en) * 2013-09-26 2021-05-04 Forschungszentrum Juelich Gmbh Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of alzheimer's disease
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
WO2018009514A1 (en) * 2016-07-06 2018-01-11 George Stantchev Apparatus and method for plant extraction
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
US20110189290A1 (en) * 2008-10-27 2011-08-04 Recombinant Technologies Llc Compositions Comprising Capture Peptides for A B-Amyloid Peptide
US20110243949A1 (en) * 2008-11-19 2011-10-06 Forschungszentrum Juelich Gmbh Composition for producing anti-amyloid beta peptide antibodies with d-peptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5968820A (en) 1997-02-26 1999-10-19 The Cleveland Clinic Foundation Method for magnetically separating cells into fractionated flow streams
WO2000063268A1 (en) 1999-04-16 2000-10-26 Wm. Marsh Rice University Poly(propylene fumarate) cross linked with poly(ethylene glycol)
AU2002225772A1 (en) 2000-11-27 2002-06-03 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
US20040143093A1 (en) * 2002-07-11 2004-07-22 Ralph Zahn Method for inducing a conformational transition in proteins, such as pathogenic/infectious proteins, and their use
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
DE102005009909A1 (de) 2005-03-01 2006-09-07 Heinrich-Heine-Universität Düsseldorf Verbindungen geeignet zur Beseitigung fehlgefalteter Proteine
DE102005031429A1 (de) 2005-07-04 2007-01-11 Heinrich-Heine-Universität Düsseldorf Verfahren zur selektiven Bestimmung pathologischer Proteinablagerungen
DE102005063175A1 (de) 2005-07-29 2007-02-01 Hans-Werner Prof. Dr. Heinrich Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung für Tiere, in der Biotechnologie (einschließlich der biologischen Forschung) und der medizinischen Diagnostik
US20070092508A1 (en) * 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
DE102006015140A1 (de) 2006-03-31 2007-10-11 Philipps-Universität Marburg Heterozyklische Verbindungen mit Wirkung gegen neurodegenerative Erkrankungen
US20100166695A1 (en) 2007-03-23 2010-07-01 The Governors Of The University Of Alberta Multivalent Heterobifunctional Polymers And Methods Of Their Use
CN101538329B (zh) * 2008-03-20 2013-01-30 中国医学科学院基础医学研究所 新的抗β-淀粉样多肽抗体的可变区序列及其编码序列
DE102009037015A1 (de) 2009-08-07 2011-02-17 Michael Hajek Vorrichtung und Verfahren zur Eliminierung von bioschädlichen Stoffen aus Körperflüssigkeiten
DE102010019336A1 (de) 2010-05-05 2011-11-10 Forschungszentrum Jülich GmbH Mittel zur Behandlung der Alzheimerschen Demenz
DE102010017130B4 (de) 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
CN102233128B (zh) * 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
JP2015518474A (ja) 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 血液、血液生産物及び器官を処置する方法
CN104380111B (zh) * 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
US20110189290A1 (en) * 2008-10-27 2011-08-04 Recombinant Technologies Llc Compositions Comprising Capture Peptides for A B-Amyloid Peptide
US20110243949A1 (en) * 2008-11-19 2011-10-06 Forschungszentrum Juelich Gmbh Composition for producing anti-amyloid beta peptide antibodies with d-peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS CHEM. NEUROSCI., 2010, VOL.1, PP.639-648, JPN6017047201, ISSN: 0003812190 *
ZHANG, GUOBAO ET AL.: "Multiple-Peptide Conjugates for Binding β-Amyloid Plaques of Alzheimer's disease", BIOCONJUGATE CHEM, vol. 14, JPN6017025548, 2003, pages 86 - 92, ISSN: 0003812191 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022529224A (ja) * 2019-04-05 2022-06-20 ファーマキュア リミテッド タンパク質凝集疾患の治療
JP2025118795A (ja) * 2019-04-05 2025-08-13 ファーマキュア リミテッド タンパク質凝集疾患の治療
JP2022158028A (ja) * 2021-04-01 2022-10-14 国立大学法人神戸大学 ペプチド結合切断活性を有する人工ペプチドおよびその利用
JP7774972B2 (ja) 2021-04-01 2025-11-25 禎弘 飯田 ペプチド結合切断活性を有する人工ペプチドおよびその利用

Also Published As

Publication number Publication date
DK3260865T3 (da) 2023-02-27
DK3260865T5 (da) 2024-10-14
JP2017222682A (ja) 2017-12-21
US10123530B2 (en) 2018-11-13
EP3260865B1 (de) 2022-12-28
JP6997160B2 (ja) 2022-02-03
US20190037835A1 (en) 2019-02-07
CN104380110A (zh) 2015-02-25
ES2938886T3 (es) 2023-04-17
WO2013150126A2 (de) 2013-10-10
US20170172139A1 (en) 2017-06-22
EP3260865A2 (de) 2017-12-27
EP2834643A2 (de) 2015-02-11
US10772321B2 (en) 2020-09-15
EP2834643B1 (de) 2019-10-23
WO2013150126A3 (de) 2014-01-03
US9591845B2 (en) 2017-03-14
EP3260865A3 (de) 2018-05-09
PL3260865T3 (pl) 2023-04-11
DK2834643T3 (da) 2020-02-03
JP6619394B2 (ja) 2019-12-11
JP2020037582A (ja) 2020-03-12
CN108926749A (zh) 2018-12-04
US20150282477A1 (en) 2015-10-08
ES2773125T3 (es) 2020-07-09

Similar Documents

Publication Publication Date Title
JP6619394B2 (ja) 血液、血液生産物及び器官を処置する方法
JP6434903B2 (ja) 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
JP6611858B2 (ja) Ｄ３から誘導されたｄ−エナンチオマーの新規ペプチド及びその使用
JP2020023510A (ja) アミロイドベータ結合性環状ペプチドおよびその使用
CN105745219B (zh) 结合β淀粉状蛋白的肽及其用于治疗和诊断阿尔茨海默痴呆症的用途
JP6714610B2 (ja) アルツハイマー型認知症の治療および／または診断のための特定のａ−ベータ種に結合するペプチド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170407

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170609

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180611